Chemed Stock Forecast, Price & News

Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CHE stock has increased by 15.7% and is now trading at $479.07.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chemed or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Chemed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chemed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) posted its earnings results on Thursday, October, 29th. The company reported $4.86 earnings per share for the quarter, beating analysts' consensus estimates of $3.97 by $0.89. The business had revenue of $528.30 million for the quarter, compared to the consensus estimate of $514.22 million. Chemed had a return on equity of 38.13% and a net margin of 13.11%. Chemed's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter last year, the company posted $3.46 earnings per share.
View Chemed's earnings history.

Chemed announced a quarterly dividend on Friday, November 6th. Stockholders of record on Monday, November 16th will be given a dividend of $0.34 per share on Monday, December 7th. This represents a $1.36 annualized dividend and a yield of 0.28%. The ex-dividend date is Friday, November 13th.
View Chemed's dividend history.

Chemed updated its FY20 earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of $18.00-18.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.35.

2 Wall Street analysts have issued 12 month price targets for Chemed's shares. Their forecasts range from $535.00 to $535.00. On average, they expect Chemed's share price to reach $535.00 in the next year. This suggests a possible upside of 11.7% from the stock's current price.
View analysts' price targets for Chemed.

Chemed saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 168,500 shares, an increase of 22.5% from the September 30th total of 137,600 shares. Based on an average daily volume of 64,900 shares, the short-interest ratio is presently 2.6 days. Currently, 1.1% of the shares of the company are short sold.
View Chemed's Short Interest.

Some companies that are related to Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), The Providence Service (PRSC), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Biosciences (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a number of retail and institutional investors. Top institutional investors include Alps Advisors Inc. (10.23%), BlackRock Inc. (9.16%), Neuberger Berman Group LLC (3.87%), Acadian Asset Management LLC (2.89%), Wells Fargo & Company MN (2.44%) and State Street Corp (2.37%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Boston Trust Walden Corp, First Trust Advisors LP, Allianz Asset Management GmbH, Acadian Asset Management LLC, Copeland Capital Management LLC, and Point72 Asset Management L.P.. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, and Spencer S Lee.
View insider buying and selling activity for Chemed.

CHE stock was purchased by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Assenagon Asset Management S.A., Kathmere Capital Management LLC, Great West Life Assurance Co. Can, North Point Portfolio Managers Corp OH, DekaBank Deutsche Girozentrale, AXA S.A., and Riverbridge Partners LLC.
View insider buying and selling activity for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $479.07.

Chemed has a market capitalization of $7.64 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe.

The official website for Chemed is www.chemed.com.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.